Archives of Public Health

Vol. 9 No. 1 (2017): Archives of Public Health
Clinical Science

E-cadherin and its role in patients with advanced serous ovarian carcinoma of the ovaries

PDF (македонски јазик)
  • Игор Алулоски
Игор Алулоски
Универзитетска клиника за гинекологија и акушерство, Скопје

Published 2017-08-19

How to Cite

1.
Алулоски Игор. E-cadherin and its role in patients with advanced serous ovarian carcinoma of the ovaries. Arch Pub Health [Internet]. 2017 Aug. 19 [cited 2024 Jul. 16];9(1):41-5. Available from: https://id-press.eu/aph/article/view/1258
Copyright Notice

Abstract

Ovarian cancer is the fifth leading cause of cancer deaths and has the highest mortality rate among gynecologic cancers in women in North America and Europe.The aim of this study wasto analyze the correlation between E-cadherin expression and clinical and pathohistological features and overall survival in advanced-stage serous ovarian carcinoma. Methods. The expression of E-cadherin was examined immunohistochemically in deparaffinized and rehydrated tissue samples from 36 patients with advanced- stage serous ovarian cancer, in whom surgery was first choice of treatment. All patients completed their chemotherapy treatment. Stage of the disease according to International Federation of Gynecology and Obstetrics (FIGO),  tumour  differentiation, number of mitoses on 10 high-power magnification fields (HPF), the size of the residual tumour, and lymphovascular invasion were included as clinicopathological characteristics. Included were only patients with serous ovarian cancer FIGO stages  III–IV. We determined the Overall survival (OS) as the time from surgery to the last follow-up date. The analyzed histological samples were retrieved from the files of the Institute of Pathology, Medical Faculty-Skopje from 2010 to 2013. We examined OS by using Kaplan–Meier method and log-rank test to assess the differences between the two E-cadherin groups, positive and negative. Multivariate analyses were done with the Cox"˜s model.Results. Statistical analysis found that E-cadherin immunoreactivity wasnot in correlation with FIGO stage, tumor grade, residual tumor volume and vascular invasion. Negative E-cadherin expression predicts shorter OS (p < 0.001). Multivariate analyses shows that negative E-cadherin expression (p< 0.001), FIGO stage (p=0.012) and residual tumor volume > 1 cm after primary cytoreductive surgery (p<0.001) are predictors of shorter OS. Conclusion. Negative E-cadherin expression seems to predict unfavorable clinical outcome in patients with advanced serous ovarian cancer as well as higher FIGO stage and residual tumor volume after primary surgery. Negative E-cadherin expression emerges as a significant independent predictor for poorer OS. In conclusion, the analysis have revealed that E-cadherin has prognostic value as a marker.
PDF (македонски јазик)

Downloads

Download data is not yet available.

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999.CA Cancer J 1999;49:8 –31.
  2. National Cancer Institute. Cancer Stat Facts: Ovarian Cancer. Available from: http://seer.cancer.gov/ statfacts/html/ovary.html
  3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin2005; 55(1):10–30.
  4. Shiozaki H, Oka H, Inoue M, et al. E-cadherin mediated adhesion system in cancer cells. Cancer 1996;
  5. : 1605–1613.
  6. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. BiochimBiophys Acta 1993; 1198: 11–26.
  7. Pignatelli M. E-cadherin. A biological marker of tumor differentiation. J Pathol 1993; 171: 81–82.
  8. Aplin AE, Howe A, Alahari SK,Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998; 50: 197-264.
  9. Takeichi M. Morphogenetic roles of the classical cadherins. CurrOpin Cell Biol1995;7:619 –27.
  10. Suzuki ST. Structural and functional diversity of cadherin superfamily involved in signal transduction pathway? J Cell Biochem 1996;61: 531–
  12. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317–21.
  13. Birchmeier W, Behrens J, Weidner KM, Frixen UH, Schipper J. Dominant and recessive genes involved in tumor cell invasion. CurrOpin Cell Biol1991;3:832–40.
  14. Okegawa T, Li Y, Pong RC, Hsieh JT. Cell adhesion proteins astumor suppressors. J Urol2002;167:1836–43.
  15. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer J Clin Invest 2002;109:987–91.
  16. Cavallaro U, Schaffhauser B, Christofori G. Cadherins and tumor progression: is it all in a switch? Cancer Lett 2002;176:123–8
  17. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. SeminOncol1998;25:281–304.
  18. Natt E, Magenis RE, Zimmer J, et al.
  19. Regional assignment of the human loci for ovumorulin (UVO) and chymotrypsinogen B (CTRB) with the help of two overlapping deletions on the long arm of chromosome 16. Cytogenet Cell Genet 1989; 50: 145–148.
  20. Takeichi M. Cadherins. A molecular family important in selective cell–cell adhesion. Ann Rev Biochem 1990; 59:237–252.
  21. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451–1455.
  22. Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 1994; 125: 1327–
  24. Ozawa M, Kemler R. Molecular organization of the Uvomorulin– catenin complex. J Cell Biol 1992; 116:
  25. –996.
  26. Kemler R. From cadherins to catenins: cytoplasmatic protein interactions and regulation of cell adhesion. Trends Genet 1993; 9:317–321.
  27. Frixen UH, Behrens J, Sachs M, et al. E-cadherin mediated cell–cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173–185.
  28. Eidelman S, Damsky CH, Wheelock MJ, Damjanov I. Expression of the cell–cell adhesion glycoprotein Cell- CAM 120/80 in normal human tissues and tumors. Am J Pathol 1989; 135:
  29. –110.
  30. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancers. Genes Chromosom Cancer
  31. ; 34: 255–268.
  32. Bankfalvi A, Krabort M, Buchwalow VA, Felszeghy E, et al. Gains and losses of adhesion molecules (CD44, E-cadherin, b-catenin) during oral carcinogenesis and tumour progression. J Pathol 2002; 198: 343–
  34. Yoshida R, Kimura N, Harada Y, Ohuchi N. The loss of E-cadherin, α and α-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001; 18: 513–520.
  35. Endo K, Eda T, Ueyama J, Otha T, et al.
  36. Immunoreactive E-cadherin, alpha- catenin, beta-catenin and gamma- catenin proteins in hepatocellular carcinoma: relationships with tumour grade, clinicopathological parameters, and patient survival. Hum Pathol 2000; 31: 558–565.
  37. Garcia del Muro X, Torregrosa A, Munoz J, Castellsague X. Prognostic value of expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer 2000; 36: 357–362.
  38. Richmond PJK, Karayiannakis AJ, Nagafuchi A, et al. Aberrant E-cadherin and a-catenin expression in prostate cancer: Correlation with patient survival. Cancer Res 1997; 57:
  39. –3193.
  40. Katagiri A, Watanabe R, Tomita Y. E-Cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer
  41. ; 71: 376–379.
  42. Pignatelli M, Ansari TW, Gunter P, et al. Loss of membranous E-cadherin expression in pancreatic cancer. correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994; 174: 243–248.
  43. Krishnadath KK, Tilanus HW, van Blankenstein M, et al. Reduced expression of the cadherin– catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997; 182:
  44. –338.
  45. von Wasielewski R, Rhein A, Werner M, et al. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997; 57: 2501–2507.
  46. Mattijssen V, Peters HM, Schalkwijk L, et al. E-cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int J Cancer 1993; 55: 580–585.
  47. Gabbert HE, Mueller W, Schneiders A, et al. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int J Cancer 1996; 69: 184–189.
  48. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998; 153: 333–339.
  49. Yoshiura K, Kanai Y, Ochai A, et al.
  50. Silencing of the E-cadherin invasion- suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 7416–7419.
  51. Hennig G, Behrens J, Truss M, et al. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 1995; 11: 475–484.
  52. Hennig G, Lowrick O, Birchmeier W, Behrens J. Mechanisms identified in the transcriptional control of epithelial gene expression. J BiolChem 1996; 271: 595–602.
  53. Matsuyoshi N, Hamaguchi M, Taniguchi S, et al. Cadherin-mediated cell–cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol
  54. ; 118: 703–714.
  55. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO- OVAR (ArbeitsgemeinschaftGynaek ologischeOnkologie Ovarian Cancer Study Group). Ann SurgOncol2010;
  56. (6):1642–1648.
  57. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2):228–247.
  58. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J SurgPathol2004; 28(4):496–504.
  59. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposedsystem in a series of 461 patients with uniform treatment and follow-up. Cancer 1998; 82(5):893–901.
  60. Peng HL, He L, Zhao X. Association of reduced immunohistochemical expression of E-cadherin with a poor ovarian cancer prognosis"”results of a meta-analysis. Asian Pac J Cancer Prev2012; 13(5):2003–2007.
  61. Ho CM, Cheng WF, Lin MC, Chen TC, Huang SH, Liu FS, Chien CC, Yu MH, Wang TY, Hsieh CY (2010) Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 20(9):1490–1497.
  62. Darai E, Scoazec JY, Walker- Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, Potet F (1997) Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 28(8):922–928
  63. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH (2006) Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int 56(2):62–70.
  64. Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofler H, Becker KF (2008) The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer 98(2):489–495.
  65. Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, ChekerovR, Braicu I, Lichtenegger W, Sehouli J. Expression andlocalization of e-cadherin in epithelial ovarian cancer. AnticancerRes 2010; 30(7):2525–2530.
  66. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS. Prognostic value of E-cadherin immunoexpression inpatients with primary ovarian carcinomas. Ann Oncol2004;
  67. (10):1535–1542.
  68. Voutilainen KA, Anttila MA, Sillanpaa SM, Ropponen KM,Saarikoski SV, Juhola MT, Kosma VM. Prognostic significanceof E-cadherin-catenin complex in epithelial ovariancancer. J ClinPathol2006; 59(5):460–467.
  69. Shim HS, Yoon BS, Cho NH. Prognostic significance ofpaired epithelial cell adhesion molecule and E-cadherin in ovarianserous carcinoma. Hum Pathol2009; 40(5):693–698.
  70. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH.Immunohistochemicalstudy of the expression of adhesion molecules inovarian serous neoplasms. PatholInt2006; 56(2):62–70.
  71. Dian D, Bruning A, Mylonas I. E-cadherin as a prognosticmarker in human serous carcinomas of the ovary: an immunohistochemicalanalysis. Arch GynecolObstet2011; 284(2):437–443.
  72. Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M,Goldberg I, Kopolovic J, Berner A. E-Cadherin complexprotein expression and survival in ovarian carcinoma. GynecolOncol2000; 79(3):362–371.
  73. Landen CN Jr, Birrer MJ, Sood AK.
  74. Early events in the pathogenesis of epithelial ovarian cancer. J ClinOncol2008; 26(6): 995–1005.
  75. Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 1998; 32(1):69–80
  76. Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S,Oka K, Konishi I. Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Human Pathol
  77. ; 35(12):1469–1476
  78. Hudson LG, Zeineldin R, Stack MS.
  79. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Met 2008; 25(6):643–655.
  80. Cheung LW, Leung PC, Wong AS.
  81. Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene
  82. ; 29(16):2427–2440.
  83. Sivertsen S, Berner A, Michael CW, Bedrossian C, Davidson B. Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol2006; 50(6):603–